Euromoney FY21 Profit Down, Lifts Dividend; Says Confident Of FY22 - Quick Facts

Euromoney Institutional Investor Plc (ERM.L), a B2B information services provider, Thursday reported that its fiscal 2021 profit before tax declined 11 percent to 26.6 million pounds from last year's 29.9 million pounds.

Earnings per share were 11.7 pence, down 56 percent from 26.6 pence a year ago.

Adjusted profit before tax was 61.4 million pounds, compared to 54.3 million pounds last year. Adjusted earnings per share were 45.5 pence, compared to 40.5 pence last year.

Revenue edged up slightly to 336.1 million pounds from prior year's 335.3 million pounds. Revenues declined 2 percent on an underlying basis.

Further, the company announced a final dividend of 12.5p, resulting in a total dividend for the year of 18.2p, up 60 percent from last year.

Looking ahead, the company said it is entering fiscal 2022 with strong momentum and confidence in the opportunity for sustainable growth as it continues to execute 3.0 strategy. Overall, the company expects FY 2022 to be another year of progress.

Demand for price reporting and essential market intelligence remains strong with good visibility on Fastmarkets and FPS subscriptions.

In FY 2022, as travel restrictions ease, the company plans more and larger physical events.

Looking further out, the company is confident in the sources of future growth and are committed to delivering high margins in the medium term.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
IBSA Pharma Inc. is recalling 27 lots of TIROSINT-SOL (levothyroxine sodium) Oral Solution to the consumer level due to subpotency, the U.S. Food and Drug Administration said. TIROSINT-SOL is indicated for Hypothyroidism and Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression. Meanwhile, the recall does not apply to TIROSINT (levothyroxine sodium) capsules. The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been receiving dialysis for at least four months. It is the first oral treatment for anemia, i.e., decreased number of red blood cells, in the given indication that has received FDA approval. German banking major Deutsche Bank AG reported Thursday a significantly higher profit in its fourth quarter and fiscal 2022, mainly reflecting a tax benefit in the U.S, despite weakness in Investment Bank and asset management revenues. The company said it recorded its highest annual profit, both before and after tax, since 2007. However, Deutsche Bank shares were losing around 4 percent...
Follow RTT